# Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia

> **NIH NIH R01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $87,227

## Abstract

PROJECT SUMMARY
Plasmodium falciparum strains with resistance to first-line artemisinin-combination therapies (ACTs) threaten
malaria control and elimination efforts across Africa, where 95% of the world's malaria cases and deaths occur.
Artemisinin resistance is mediated by mutations in the pfkelch13 (K13) gene that have only recently impacted
the region. Concerning K13 mutations have now been confirmed in Africa, including emergence and expansion
of the candidate artemisinin-resistance K13 R622I mutation in the Horn of Africa (HoA). Increasing reports from
the HoA by us and others also indicate that “diagnosis resistant” strains that escape detection by widely used
rapid diagnostic tests due to deletions of the histidine-rich protein 2/3 (pfhrp2/3) genes are now established
across the region. The dual emergence of drug and diagnostic resistance mutations threatens frontline test-
and-treat strategies and may have profound impacts on malaria control. Improved understanding of the
determinants of infection by R622I parasites is needed to inform clinical practice and policy decisions. In
collaboration with the Ethiopian Public Health Institute, the technical arm of the Ethiopia Federal Ministry of
Health, and leading academic partners, we will conduct surveys of people presenting to health facilities with
falciparum malaria across Ethiopia and achieve the following Aims. In Aim 1, we will elucidate risk factors for
infection by artemisinin-resistant P. falciparum, including whether the presence or absence of pfhrp2/3
deletions impacts risk. We will develop a clinical risk tool to help predict who may be infected by an artemisinin-
resistant parasite. Such a tool could be used for targeted implementation of antimalarial treatment options
designed to overcome resistance and prevent its spread, such as triple ACT that employs two partner drugs
alongside an artemisinin derivative. In Aim 2, we will determine the impact of K13 R622I on drug resistance
and parasite fitness in pfhrp2/3-deleted and intact parasites. In Aim 3, we will develop a predictive model of the
future spread of artemisinin resistance within and out of the HoA, focusing first on development of data/models
of human and parasite migration and then integrating in vivo data from Aim 1 and in vitro data from Aim 2.
Together, these Aims will improve our understanding of the epidemiology and drivers of emerging artemisinin
resistance in the HoA and produce tools that can be used by malaria programs to identify, predict, and respond
to emerging drug-resistant strains in Africa.

## Key facts

- **NIH application ID:** 11052078
- **Project number:** 3R01AI177791-02S1
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** Jonathan Boyd Parr
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $87,227
- **Award type:** 3
- **Project period:** 2023-06-09 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11052078

## Citation

> US National Institutes of Health, RePORTER application 11052078, Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia (3R01AI177791-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11052078. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*